![]()
|
|
||||||||
J. Biol. Chem., Vol. 279, Issue 32, 33079-33084, August 6, 2004
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||



¶
From the
Departments of
Nutritional Sciences and
Medical Biophysics, University of Toronto, Toronto, Ontario M5S 3E2, Canada
Malignant cells are known to have elevated rates of mevalonate synthesis because of increased levels and catalytic efficiency of 3-hydroxy-3-methylglutaryl-CoA reductase. Whether this increased mevalonate synthesis occurs as a consequence of increased requirements for a mevalonate-derived metabolite in response to rapid growth or whether mevalonate promotes the growth of tumor cells is unknown. To address this question, we administered mevalonate via miniosmotic pumps to nude mice inoculated with MDA-MB-435 human cancer cells. After 13 weeks of growth, tumors in mevalonate-treated mice were significantly larger than tumors in saline-treated, control mice (1.52 ± 0.26 g versus 0.81 ± 0.27 g respectively, p < 0.05). The cancer cells treated in culture with mevalonate also demonstrated increased proliferation rates associated with accelerated entry of cells into S phase. These cells had enhanced total and cyclin A-immunoprecipitable cyclin-dependent kinase-2 (CDK-2) activity, increased activating phosphorylation of CDK-2, and decreased inhibitory binding of CDK-2 to p21Cip1. Our findings demonstrate that mevalonate promotes tumor growth and suggest that an increase in mevalonate synthesis in extrahepatic tissues following cholesterol-lowering therapy may explain the elevated risk of cancer shown in some studies.
Received for publication, January 1, 2004 , and in revised form, May 19, 2004.
* This work was supported by U. S. Army Medical Research Acquisition Activity Grant DAMD17-99-1-9409. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
¶ Recipient of a Natural Sciences and Engineering Research Council of Canada Industrial Research Chair and supported by the member companies of the program in Food Safety, Nutrition and Regulatory Affairs of the University of Toronto. To whom correspondence should be addressed: Dept. of Nutritional Sciences, University of Toronto, FitzGerald Bldg., 150 College St., Toronto, Ontario M5S 3E2, Canada. Tel.: 416-978-8195; Fax: 416-971-2366; E-mail: m.archer{at}utoronto.ca.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
J. Montero, A. Morales, L. Llacuna, J. M. Lluis, O. Terrones, G. Basanez, B. Antonsson, J. Prieto, C. Garcia-Ruiz, A. Colell, et al. Mitochondrial Cholesterol Contributes to Chemotherapy Resistance in Hepatocellular Carcinoma Cancer Res., July 1, 2008; 68(13): 5246 - 5256. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Villagra, N. Ulloa, X. Zhang, Z. Yuan, E. Sotomayor, and E. Seto Histone Deacetylase 3 Down-regulates Cholesterol Synthesis through Repression of Lanosterol Synthase Gene Expression J. Biol. Chem., December 7, 2007; 282(49): 35457 - 35470. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Adam, N. K. Mukhopadhyay, J. Kim, D. Di Vizio, B. Cinar, K. Boucher, K. R. Solomon, and M. R. Freeman Cholesterol Sensitivity of Endogenous and Myristoylated Akt Cancer Res., July 1, 2007; 67(13): 6238 - 6246. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. O. Ward, D. A. Delker, S. D. Hester, S.-F. Thai, D. C. Wolf, J. W. Allen, and S. Nesnow Transcriptional Profiles in Liver from Mice Treated with Hepatotumorigenic and Nonhepatotumorigenic Triazole Conazole Fungicides: Propiconazole, Triadimefon, and Myclobutanil Toxicol Pathol, December 1, 2006; 34(7): 863 - 878. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Duncan, A. El-Sohemy, and M. C. Archer Statins and the Risk of Cancer JAMA, June 21, 2006; 295(23): 2720 - 2720. [Full Text] [PDF] |
||||
![]() |
K. E. Morris, L. M. Schang, and D. N. Brindley Lipid Phosphate Phosphatase-2 Activity Regulates S-phase Entry of the Cell Cycle in Rat2 Fibroblasts J. Biol. Chem., April 7, 2006; 281(14): 9297 - 9306. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. C. Li, M. J. Park, S.-K. Ye, C.-W. Kim, and Y.-N. Kim Elevated Levels of Cholesterol-Rich Lipid Rafts in Cancer Cells Are Correlated with Apoptosis Sensitivity Induced by Cholesterol-Depleting Agents Am. J. Pathol., April 1, 2006; 168(4): 1107 - 1118. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Duncan, A. El-Sohemy, and M. C. Archer Statins and Cancer Development Cancer Epidemiol. Biomarkers Prev., August 1, 2005; 14(8): 1897 - 1898. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |